- Q1 2024 Regenxbio Inc Earnings Call TranscriptMay 08, 2024€15.7 (+0.64%)Earnings
- Regenxbio Inc To Discuss Interim Clinical Data TranscriptMar 05, 2024
- Q4 2023 Regenxbio Inc Earnings Call TranscriptFeb 27, 2024€16.8 (+5.00%)Earnings
- Regenxbio Inc Interim Data Update TranscriptJan 16, 2024
- Regenxbio Inc at Stifel Healthcare Conference TranscriptNov 14, 2023
- Q3 2023 Regenxbio Inc Earnings Call TranscriptNov 08, 2023€15.3 (+4.79%)Earnings
- Regenxbio Inc Interim Data Update TranscriptNov 06, 2023
- Regenxbio Inc at World Muscle Society 2023 Data Update TranscriptOct 03, 2023
- Regenxbio Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Regenxbio Inc Earnings Call TranscriptAug 02, 2023€17.2Earnings
- Regenxbio Inc to Host Virtual Investor Day TranscriptJul 11, 2023
- Regenxbio Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Regenxbio Inc at Barclays Virtual Gene Editing & Therapy Summit TranscriptMay 24, 2023
- Regenxbio Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 16, 2023
- Regenxbio Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Regenxbio Inc Earnings Call TranscriptMay 03, 2023€17.7 (-2.75%)Earnings
- Regenxbio Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) TranscriptApr 25, 2023
- Regenxbio Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Q4 2022 Regenxbio Inc Earnings Call TranscriptFeb 28, 2023Earnings
- Regenxbio Inc To Discuss Interim Data Update Call TranscriptFeb 11, 2023
- Regenxbio Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Regenxbio Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 08, 2022
- Regenxbio Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Q3 2022 Regenxbio Inc Earnings Call TranscriptNov 03, 2022€24.6 (-1.60%)Earnings
- Regenxbio Inc To Discuss RGX-314 For The Treatment Of Wet AMD Call TranscriptOct 03, 2022
- Regenxbio Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Q2 2022 Regenxbio Inc Earnings Call TranscriptAug 03, 2022€31.2 (+4.00%)Earnings
- Regenxbio Inc at UBS Global Healthcare Conference TranscriptMay 24, 2022
- Regenxbio Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q1 2022 Regenxbio Inc Earnings Call TranscriptMay 04, 2022€27Earnings
- Regenxbio Inc at Barclays Global Healthcare Conference TranscriptMar 17, 2022
- Q4 2021 Regenxbio Inc Earnings Call TranscriptMar 01, 2022€23.27 (+2.51%)Earnings
- Regenxbio Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- Q3 2021 Regenxbio Inc Earnings Call TranscriptNov 02, 2021€30.96 (+1.64%)Earnings
- Regenxbio Inc at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- Regenxbio Inc KOL Conference Call to Discuss RGX-314 Data Presentations TranscriptOct 01, 2021
- Regenxbio Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- Regenxbio Inc Call to Discuss Eye Care Collaboration with Abbvie Inc TranscriptSep 13, 2021
- Q2 2021 Regenxbio Inc Earnings Call TranscriptAug 09, 2021€26.39 (-1.53%)Earnings
- Regenxbio Inc at Bank of America NAPA Healthcare Conference (Virtual) TranscriptJun 16, 2021
- Regenxbio Inc at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Regenxbio Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 12, 2021
- Q1 2021 Regenxbio Inc Earnings Call TranscriptMay 05, 2021€27.43 (-2.11%)Earnings
- Regenxbio Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 09, 2021
- Q4 2020 Regenxbio Inc Earnings Call TranscriptMar 01, 2021€33.76 (+3.12%)Earnings
- Regenxbio Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Regenxbio Inc at Barclays Virtual Gene Editing & Gene Therapy Summit TranscriptNov 16, 2020
- Regenxbio Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 12, 2020
- Q3 2020 Regenxbio Inc Earnings Call TranscriptNov 04, 2020€24.45 (+2.69%)Earnings
- Regenxbio Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Q2 2020 Regenxbio Inc Earnings Call TranscriptAug 06, 2020€28.49 (+0.35%)Earnings
- Regenxbio Inc RGX-314 Update Call TranscriptAug 04, 2020
- Q1 2020 Regenxbio Inc Earnings Call TranscriptMay 07, 2020€38.14 (-3.27%)Earnings
- Regenxbio Inc REGENXBIO RGX-314 Phase I/IIa Trial Update TranscriptApr 22, 2020
- Regenxbio Inc at Barclays Global Healthcare Conference TranscriptMar 11, 2020
- Q4 2019 Regenxbio Inc Earnings Call TranscriptFeb 26, 2020€43.92 (-5.47%)Earnings
- Q3 2019 Regenxbio Inc Earnings Call TranscriptNov 05, 2019€33.16 (-0.78%)Earnings
- Regenxbio Inc at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Regenxbio Inc, Uniqure NV at Citi Biotech Conference TranscriptSep 04, 2019
- Q2 2019 Regenxbio Inc Earnings Call TranscriptAug 07, 2019€36.17 (+2.12%)Earnings
- Regenxbio Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 15, 2019
- Q1 2019 Regenxbio Inc Earnings Call TranscriptMay 07, 2019€46.06 (+0.83%)Earnings
- Regenxbio Inc at Barclays Global Healthcare Conference TranscriptMar 13, 2019
- Q4 2018 Regenxbio Inc Earnings Call TranscriptFeb 27, 2019€46.09 (-2.23%)Earnings
- Regenxbio Inc Analyst and Investor Event TranscriptFeb 21, 2019
Regenxbio Inc Interim Data Update Transcript
Thank you for standing by, and welcome to the REGENXBIO interim data update from Phase II AAVIATE trial of ABBV-RGX-314 for treatment of wet AMD using suprachoroidal delivery Hawaiian Eye and Retina 2024 Conference Call. (Operator Instructions)
As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Mr. Ken Mills, President and CEO of REGENXBIO. Please go ahead, sir.
&
Welcome, everyone, to our Hawaiian Eye and Retina event. I am Ken Mills, CEO of REGENXBIO, and I'm pleased to introduce our agenda and make some opening remarks.
In November, REGENXBIO announced the pipeline prioritization and corporate restructuring plan that will enable us to focus our capabilities and resources on large commercial opportunities where our product candidates are differentiated, can be expedited, and support meaningful value generation soon and for the long term. Our highest priority programs are ABBV-RGX-314 for the treatment of retinal
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)